ChitogenX Inc. (CHGX.CN)
CAD 0.01
(0.0%)
CAD 0.01
(0.0%)
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2023 | 6.71 Million CAD | -36.57% |
| 2022 | 10.58 Million CAD | 28.61% |
| 2021 | 8.22 Million CAD | 62.01% |
| 2020 | 5.07 Million CAD | 37.76% |
| 2019 | 3.68 Million CAD | 68.09% |
| 2018 | 2.19 Million CAD | 60.63% |
| 2017 | 1.36 Million CAD | -32.2% |
| 2016 | 2.01 Million CAD | 40.66% |
| 2015 | 1.43 Million CAD | 0.0% |
| Year | Total Liabilities | Total Liabilities Growth |
|---|---|---|
| 2024 Q2 | 7.22 Million CAD | 2.91% |
| 2024 Q1 | 7.02 Million CAD | 4.59% |
| 2023 Q1 | 10.82 Million CAD | 2.34% |
| 2023 FY | 6.71 Million CAD | -36.57% |
| 2023 Q2 | 6.61 Million CAD | -38.96% |
| 2023 Q4 | 6.71 Million CAD | -0.03% |
| 2023 Q3 | 6.71 Million CAD | 1.57% |
| 2022 Q2 | 7.68 Million CAD | -1.98% |
| 2022 Q4 | 10.58 Million CAD | 22.18% |
| 2022 FY | 10.58 Million CAD | 28.61% |
| 2022 Q1 | 7.84 Million CAD | -4.68% |
| 2022 Q3 | 8.66 Million CAD | 12.66% |
| 2021 Q1 | 5.26 Million CAD | 3.76% |
| 2021 FY | 8.22 Million CAD | 62.01% |
| 2021 Q4 | 8.22 Million CAD | 12.99% |
| 2021 Q3 | 7.28 Million CAD | 20.03% |
| 2021 Q2 | 6.06 Million CAD | 15.13% |
| 2020 Q3 | 3.99 Million CAD | -12.81% |
| 2020 Q1 | 4.11 Million CAD | 11.64% |
| 2020 Q2 | 4.58 Million CAD | 11.37% |
| 2020 Q4 | 5.07 Million CAD | 27.08% |
| 2020 FY | 5.07 Million CAD | 37.76% |
| 2019 Q1 | 2.17 Million CAD | -0.77% |
| 2019 Q3 | 3.41 Million CAD | 20.54% |
| 2019 Q4 | 3.68 Million CAD | 7.9% |
| 2019 Q2 | 2.83 Million CAD | 30.24% |
| 2019 FY | 3.68 Million CAD | 68.09% |
| 2018 Q3 | 1.26 Million CAD | 46.5% |
| 2018 Q1 | 1.35 Million CAD | -0.96% |
| 2018 FY | 2.19 Million CAD | 60.63% |
| 2018 Q4 | 2.19 Million CAD | 73.61% |
| 2018 Q2 | 862.14 Thousand CAD | -36.24% |
| 2017 Q2 | 1.52 Million CAD | -6.28% |
| 2017 Q1 | 1.62 Million CAD | -19.3% |
| 2017 FY | 1.36 Million CAD | -32.2% |
| 2017 Q4 | 1.36 Million CAD | -2.08% |
| 2017 Q3 | 1.39 Million CAD | -8.46% |
| 2016 Q4 | 2.01 Million CAD | 18.56% |
| 2016 Q3 | 1.69 Million CAD | -1.64% |
| 2016 Q1 | 1.18 Million CAD | -17.08% |
| 2016 FY | 2.01 Million CAD | 40.66% |
| 2016 Q2 | 1.72 Million CAD | 45.46% |
| 2015 Q4 | 1.43 Million CAD | 0.0% |
| 2015 FY | 1.43 Million CAD | 0.0% |
| Name | Total Liabilities | Total Liabilities Difference |
|---|---|---|
| Algernon Pharmaceuticals Inc. | 2.71 Million CAD | -146.786% |
| Asep Medical Holdings Inc | 3.05 Million CAD | -119.931% |
| BetterLife Pharma Inc. | 8.02 Million CAD | 16.315% |
| BioVaxys Technology Corp. | 3.48 Million CAD | -92.567% |
| Rapid Dose Therapeutics Corp. | 5.04 Million CAD | -33.092% |
| Defence Therapeutics Inc. | 4.06 Million CAD | -65.24% |
| Entheon Biomedical Corp. | 85.32 Thousand CAD | -7766.301% |
| Gemina Laboratories Ltd. | 3.04 Million CAD | -120.682% |
| Glow Lifetech Corp. | 2.34 Million CAD | -186.087% |
| Lexston Life Sciences Corp. | 39.86 Thousand CAD | -16735.135% |
| Pharmala Biotech Holdings Inc. | 1.02 Million CAD | -552.27% |
| Doseology Sciences Inc. | 82.49 Thousand CAD | -8036.547% |
| MYND Life Sciences Inc. | 5.77 Million CAD | -16.231% |
| Nova Mentis Life Science Corp. | 841.66 Thousand CAD | -697.47% |
| PharmaTher Holdings Ltd. | 252.9 Thousand CAD | -2554.003% |
| PreveCeutical Medical Inc. | 5.95 Million CAD | -12.623% |
| Telescope Innovations Corp. | 1.35 Million CAD | -396.807% |